|
Engineered enzyme therapy for targeted reduction of plasma homocysteine in metabolic disorders
This technology is a specially engineered human enzyme, modified and PEGylated to break down excess homocysteine in the blood, offering a new treatment for homocystinuria and hyperhomocysteinemia with improved effectiveness and dosing flexibility.
Background
Homocystinuria and hyperhomocysteinemia are metabolic disorders characterized by elevated...
|
|
Thin film freezing technology for stable dry formulations of mRNA therapeutics
A thin film freezing method transforms mRNA and lipid nanoparticles into stable dry powders that retain their effectiveness and size. This eliminates the need for ultra-cold storage, allowing the powders to be inhaled or reconstituted, improving the distribution of mRNA therapies.
Background
mRNA therapeutics represent a groundbreaking advancement...
|
|
Nanotech for enhanced diagnostic imaging and therapeutic applications
Liposomal J-aggregates of Indocyanine Green are nanoparticles designed for enhanced photoacoustic imaging and photothermal therapy. They offer improved photostability, longer circulation, and efficient heating, hence their promise for diagnostic and therapeutic applications.
Background
Photoacoustic imaging (PAI) is a promising non-invasive clinical...
|
|
Nanoparticle technology for sustained release of therapeutic agents
This invention describes lipid-based nanoparticles designed for encapsulating and slowly releasing therapeutic agents, such as siRNA, to treat diseases. These nanoparticles enhance drug delivery efficiency and minimize rapid release, improving treatment outcomes and reducing side effects.
Background
Chronic inflammation-related diseases, such as rheumatoid...
|
|
A pharmaceutical compound for targeted cancer therapy using nucleobase analog derivatives with omega-3 fatty acids
The invention describes compounds combining nucleobase analogs with omega-3 fatty acids, enhancing cancer treatment efficacy, particularly for pancreatic cancer. These compounds improve stability and solubility and demonstrate significant anti-cancer activity, offering potential for targeted therapy.
Background
Pancreatic cancer presents a significant...
|
|
Pegylated aminoglycoside compounds for enhanced treatment of biofilm infections
Pegylated aminoglycoside compounds, like m-PEG-tobramycin, combine antibiotics with polyethylene glycol to enhance solubility, stability, and bioavailability, effectively penetrating and disrupting biofilm infections resistant to standard treatments.
Background
Biofilm-associated infections present a significant challenge in medical and industrial...
|
|
Nasal-based rapid testosterone delivery system
A nasal spray formulation delivers testosterone or its derivatives quickly into the bloodstream via the nasal route, using water, medium-chain triglycerides, and a PEGylated surfactant. This method efficiently treats hypogonadism, low libido, and anxiety disorders .
Background
Testosterone is a crucial hormone in the human body, playing a significant...
|
|
Human enzyme-mediated depletion of serine in cancer
Engineered human serine dehydratase enzymes are designed to efficiently degrade serine, an amino acid crucial to cancer cell metabolism, and inhibit cancer growth. These enzymes, with improved stability, activity, and bioavailability, offer a targeted cancer treatment option with fewer adverse effects.
Background
Traditional chemotherapeutic...
|
|
Advanced PAI contrast agents for early cancer detection
This technology involves creating biodegradable nanoparticles (nanocapsules) that selectively target diseased cells, such as cancer cells, for imaging and treatment. These nanocapsules contain indocyanine green (ICG) dye aggregates, which are stable and offer high contrast when using near-infrared photoacoustic imaging, enabling the detection...
|
|
Lung mucus-penetrating peptides
Problem
Nucleic acid therapy has the potential to treat genetic diseases that affect the lungs. In order to effectively deliver genetic material to lung cells, gene delivery systems must be able to overcome the mucus barrier and directly target cells harboring the genetic mutation causing the disease state. Past efforts have focused to penetrate the...
|
